Mounjaro®
Starting from £179.99/mo
Start journey Learn moreWeight loss injections such as tirzepatide (Mounjaro) and semaglutide (Wegovy) can improve cholesterol profiles as part of broader metabolic improvements — but the mechanism is mostly indirect, running through the body weight you lose rather than a direct drug action on cholesterol pathways. Clinical trials have recorded meaningful reductions in LDL and triglycerides alongside significant weight loss. These are prescription-only medicines: a GPhC-registered prescriber decides whether treatment is clinically appropriate for you following a full assessment. If high cholesterol is part of the picture, that conversation matters.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
The most reliable route from GLP-1 treatment to lower cholesterol is weight loss itself. Excess body fat, particularly visceral fat around the organs, drives the liver to overproduce very-low-density lipoprotein (VLDL), which in turn raises LDL cholesterol and triglycerides. As that fat mass shrinks, the liver's output normalises, and blood lipid levels often follow.
In the SURMOUNT-1 trial (the pivotal study for tirzepatide, published in the New England Journal of Medicine) participants lost an average of around 20–21% of body weight at the 15mg dose over 72 weeks. Alongside that loss, the trial recorded statistically significant reductions in triglycerides and LDL, together with increases in HDL (the so-called good cholesterol). The pattern was dose-dependent: larger weight reduction tracked with larger lipid improvement.
For semaglutide, the STEP 1 trial (also published in the NEJM) reported average weight loss of around 15% at the 2.4mg weekly dose, again with broadly favourable lipid changes. The NHS semaglutide patient information page notes that semaglutide affects appetite regulation and slows gastric emptying, the metabolic ripple from that goes well beyond blood sugar.
Worth knowing: the lipid benefits in both trials were measured on top of whatever statins or other lipid-lowering medicines participants were already taking. These injections are not a replacement for prescribed cholesterol treatment.
Dyslipidaemia) the clinical term for an abnormal cholesterol or triglyceride profile, sits on the list of weight-related conditions that can make someone eligible for licensed weight-loss treatment even at a lower BMI. Under the licences for Mounjaro and Wegovy, adults with a BMI of 27 or above plus at least one such condition may qualify, rather than needing a BMI of 30.
That threshold matters in practice. Someone with a BMI of 28 who also has raised LDL and blood pressure may be a good candidate for assessment, even though their BMI alone wouldn't usually prompt a conversation about these medicines. A prescriber looks at the whole clinical picture, not just the number on the scale.
For a fuller breakdown of how dyslipidaemia fits into the eligibility framework for Mounjaro specifically, our dedicated page on weight loss injections and high cholesterol covers the evidence in more detail. NICE's appraisal of tirzepatide (TA1026) also describes the comorbidity criteria and the ethnic-background adjustments that apply, worth reading if you're unsure where you sit.
It's also worth noting that weight-related cholesterol elevation is different from familial hypercholesterolaemia, which is genetic. GLP-1 medicines are not specifically studied or licensed for the genetic form; that requires separate specialist input.
Cholesterol doesn't change overnight. Most people see lipid improvements tracked over the same months that significant weight loss builds, typically from month three or four onward, once the body is consistently losing adipose tissue. Your GP or prescriber will usually monitor lipids through routine blood tests; if you're starting a GLP-1 medicine privately, tell your GP so they can include lipid monitoring in your next review.
The licensed weight loss injections available in the UK all work on an escalating dose schedule: tirzepatide begins at 2.5mg weekly (a settling-in dose, not a therapeutic plateau), and the prescriber titrates upward over weeks and months. The lipid data from trials reflects the higher maintenance doses, so patience and consistency with the titration schedule matter.
Gastrointestinal side effects are common in the early weeks, nausea, constipation, reflux and changes in appetite. Most settle as the body adjusts, but they can affect what you eat, which in turn influences dietary cholesterol intake. Some people find they naturally reduce saturated fat because their appetite for rich food falls, and if you're curious about whether steroid injections can cause weight loss rather than promote it, that question has a separate answer worth understanding before comparing treatment types. That's an additional, if anecdotal, benefit that goes alongside the pharmacological effect. For detailed side-effect information, the NHS tirzepatide medicines page is the clearest patient-level reference available.
If high cholesterol is part of why you're looking at weight loss treatment, it's worth being honest about that in your consultation. At nume, every consultation is read by a real prescriber (not processed by an algorithm) and that context shapes the clinical assessment. Someone managing dyslipidaemia alongside excess weight has a different risk profile from someone whose main concern is BMI alone.
The treatment options we offer are Mounjaro and Wegovy, both sourced through the licensed UK supply chain. Once a prescriber approves treatment, your pen is dispatched the same day (if your consultation is submitted before noon on a weekday) and arrives the next working day via DPD, in plain unbranded packaging with a discreet tracking notification on your phone. Nothing about the box signals what's inside.
For context on how private treatment pricing works and what a transparent fee should include, the weight loss treatment overview covers costs, what's included, and what to watch for with providers who lead on price. People searching for a weight loss injection that is properly licensed and clinically supervised will find a breakdown of what responsible provision looks like there too. One transparent price (consultation, prescription, medicine, delivery and 7-day aftercare) is the only model that makes sense for a prescription medicine.
Cholesterol is a manageable condition, and for many people weight loss is the single most effective lever. If you'd like a prescriber to look at whether these medicines are right for your situation, speak to our prescribers through a free consultation, same day, no waiting list. Patients based in the Midlands can also read more about accessing treatment through our pages on weight loss injections in Worcester and weight loss injections in Leicester, both of which cover local availability and how the process works.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.